List of Tables
Table 1. Global Age Related Macular Degeneration Drug Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Age Related Macular Degeneration Drug Market Value by Clinical Type (US$ Million), 2025 vs 2032
Table 3. Global Age Related Macular Degeneration Drug Market Value by Administration Route (US$ Million), 2025 vs 2032
Table 4. Global Age Related Macular Degeneration Drug Market Value by Application (US$ Million), 2025 vs 2032
Table 5. Global Age Related Macular Degeneration Drug Market Competitive Situation by Manufacturers in 2025
Table 6. Global Age Related Macular Degeneration Drug Sales (K Dose) of Key Manufacturers (2021–2026)
Table 7. Global Age Related Macular Degeneration Drug Sales Market Share by Manufacturers (2021–2026)
Table 8. Global Age Related Macular Degeneration Drug Revenue (US$ Million) by Manufacturers (2021–2026)
Table 9. Global Age Related Macular Degeneration Drug Revenue Share by Manufacturers (2021–2026)
Table 10. Global Market Age Related Macular Degeneration Drug Average Price (USD/Unit) of Key Manufacturers (2021–2026)
Table 11. Global Key Players of Age Related Macular Degeneration Drug, Industry Ranking, 2023 vs 2024 vs 2025
Table 12. Global Key Manufacturers of Age Related Macular Degeneration Drug, Manufacturing Sites and Headquarters
Table 13. Global Key Manufacturers of Age Related Macular Degeneration Drug, Product Types and Applications
Table 14. Global Key Manufacturers of Age Related Macular Degeneration Drug, Date of Entry into the Industry
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Age Related Macular Degeneration Drug Companies by Tier (Tier 1, Tier 2, Tier 3), based on Age Related Macular Degeneration Drug Revenue, 2025
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 18. Global Age Related Macular Degeneration Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 19. Global Age Related Macular Degeneration Drug Sales by Region (K Dose), 2021–2026
Table 20. Global Age Related Macular Degeneration Drug Sales Market Share by Region (2021–2026)
Table 21. Global Age Related Macular Degeneration Drug Sales by Region (K Dose), 2027–2032
Table 22. Global Age Related Macular Degeneration Drug Sales Market Share by Region (2027–2032)
Table 23. Global Age Related Macular Degeneration Drug Revenue by Region (US$ Million), 2021–2026
Table 24. Global Age Related Macular Degeneration Drug Revenue Market Share by Region (2021–2026)
Table 25. Global Age Related Macular Degeneration Drug Revenue by Region (US$ Million), 2027–2032
Table 26. Global Age Related Macular Degeneration Drug Revenue Market Share by Region (2027–2032)
Table 27. North America Age Related Macular Degeneration Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 28. North America Age Related Macular Degeneration Drug Sales by Country (K Dose), 2021–2026
Table 29. North America Age Related Macular Degeneration Drug Sales by Country (K Dose), 2027–2032
Table 30. North America Age Related Macular Degeneration Drug Revenue by Country (US$ Million), 2021–2026
Table 31. North America Age Related Macular Degeneration Drug Revenue by Country (US$ Million), 2027–2032
Table 32. Europe Age Related Macular Degeneration Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 33. Europe Age Related Macular Degeneration Drug Sales by Country (K Dose), 2021–2026
Table 34. Europe Age Related Macular Degeneration Drug Sales by Country (K Dose), 2027–2032
Table 35. Europe Age Related Macular Degeneration Drug Revenue by Country (US$ Million), 2021–2026
Table 36. Europe Age Related Macular Degeneration Drug Revenue by Country (US$ Million), 2027–2032
Table 37. Asia Pacific Age Related Macular Degeneration Drug Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 38. Asia Pacific Age Related Macular Degeneration Drug Sales by Region (K Dose), 2021–2026
Table 39. Asia Pacific Age Related Macular Degeneration Drug Sales by Region (K Dose), 2027–2032
Table 40. Asia Pacific Age Related Macular Degeneration Drug Revenue by Region (US$ Million), 2021–2026
Table 41. Asia Pacific Age Related Macular Degeneration Drug Revenue by Region (US$ Million), 2027–2032
Table 42. Latin America Age Related Macular Degeneration Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 43. Latin America Age Related Macular Degeneration Drug Sales by Country (K Dose), 2021–2026
Table 44. Latin America Age Related Macular Degeneration Drug Sales by Country (K Dose), 2027–2032
Table 45. Latin America Age Related Macular Degeneration Drug Revenue by Country (US$ Million), 2021–2026
Table 46. Latin America Age Related Macular Degeneration Drug Revenue by Country (US$ Million), 2027–2032
Table 47. Middle East and Africa Age Related Macular Degeneration Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 48. Middle East and Africa Age Related Macular Degeneration Drug Sales by Country (K Dose), 2021–2026
Table 49. Middle East and Africa Age Related Macular Degeneration Drug Sales by Country (K Dose), 2027–2032
Table 50. Middle East and Africa Age Related Macular Degeneration Drug Revenue by Country (US$ Million), 2021–2026
Table 51. Middle East and Africa Age Related Macular Degeneration Drug Revenue by Country (US$ Million), 2027–2032
Table 52. Global Age Related Macular Degeneration Drug Sales (K Dose) by Type (2021–2026)
Table 53. Global Age Related Macular Degeneration Drug Sales (K Dose) by Type (2027–2032)
Table 54. Global Age Related Macular Degeneration Drug Sales Market Share by Type (2021–2026)
Table 55. Global Age Related Macular Degeneration Drug Sales Market Share by Type (2027–2032)
Table 56. Global Age Related Macular Degeneration Drug Revenue (US$ Million) by Type (2021–2026)
Table 57. Global Age Related Macular Degeneration Drug Revenue (US$ Million) by Type (2027–2032)
Table 58. Global Age Related Macular Degeneration Drug Revenue Market Share by Type (2021–2026)
Table 59. Global Age Related Macular Degeneration Drug Revenue Market Share by Type (2027–2032)
Table 60. Global Age Related Macular Degeneration Drug Price (USD/Unit) by Type (2021–2026)
Table 61. Global Age Related Macular Degeneration Drug Price (USD/Unit) by Type (2027–2032)
Table 62. Global Age Related Macular Degeneration Drug Sales (K Dose) by Application (2021–2026)
Table 63. Global Age Related Macular Degeneration Drug Sales (K Dose) by Application (2027–2032)
Table 64. Global Age Related Macular Degeneration Drug Sales Market Share by Application (2021–2026)
Table 65. Global Age Related Macular Degeneration Drug Sales Market Share by Application (2027–2032)
Table 66. Global Age Related Macular Degeneration Drug Revenue (US$ Million) by Application (2021–2026)
Table 67. Global Age Related Macular Degeneration Drug Revenue (US$ Million) by Application (2027–2032)
Table 68. Global Age Related Macular Degeneration Drug Revenue Market Share by Application (2021–2026)
Table 69. Global Age Related Macular Degeneration Drug Revenue Market Share by Application (2027–2032)
Table 70. Global Age Related Macular Degeneration Drug Price (USD/Unit) by Application (2021–2026)
Table 71. Global Age Related Macular Degeneration Drug Price (USD/Unit) by Application (2027–2032)
Table 72. Regeneron Pharmaceuticals Company Information
Table 73. Regeneron Pharmaceuticals Description and Business Overview
Table 74. Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 75. Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Product
Table 76. Regeneron Pharmaceuticals Recent Developments/Updates
Table 77. Bayer HealthCare Company Information
Table 78. Bayer HealthCare Description and Business Overview
Table 79. Bayer HealthCare Age Related Macular Degeneration Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 80. Bayer HealthCare Age Related Macular Degeneration Drug Product
Table 81. Bayer HealthCare Recent Developments/Updates
Table 82. Novartis Company Information
Table 83. Novartis Description and Business Overview
Table 84. Novartis Age Related Macular Degeneration Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 85. Novartis Age Related Macular Degeneration Drug Product
Table 86. Novartis Recent Developments/Updates
Table 87. Roche Company Information
Table 88. Roche Description and Business Overview
Table 89. Roche Age Related Macular Degeneration Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 90. Roche Age Related Macular Degeneration Drug Product
Table 91. Roche Recent Developments/Updates
Table 92. Kanghong Pharma Company Information
Table 93. Kanghong Pharma Description and Business Overview
Table 94. Kanghong Pharma Age Related Macular Degeneration Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 95. Kanghong Pharma Age Related Macular Degeneration Drug Product
Table 96. Kanghong Pharma Recent Developments/Updates
Table 97. Key Raw Materials Lists
Table 98. Raw Materials Key Suppliers Lists
Table 99. Age Related Macular Degeneration Drug Distributors List
Table 100. Age Related Macular Degeneration Drug Customers List
Table 101. Age Related Macular Degeneration Drug Market Trends
Table 102. Age Related Macular Degeneration Drug Market Drivers
Table 103. Age Related Macular Degeneration Drug Market Challenges
Table 104. Age Related Macular Degeneration Drug Market Restraints
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
Table 108. Authors List of This Report
List of Figures
Figure 1. Product Picture of Age Related Macular Degeneration Drug
Figure 2. Global Age Related Macular Degeneration Drug Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Age Related Macular Degeneration Drug Market Share by Type: 2025 & 2032
Figure 4. Lucentis Product Picture
Figure 5. Eylea Product Picture
Figure 6. Avastin Product Picture
Figure 7. Others Product Picture
Figure 8. Global Age Related Macular Degeneration Drug Market Value by Clinical Type (US$ Million), 2021–2032
Figure 9. Global Age Related Macular Degeneration Drug Market Share by Clinical Type: 2025 vs 2032
Figure 10. Wet ADM Product Picture
Figure 11. Dry ADM Product Picture
Figure 12. Global Age Related Macular Degeneration Drug Market Value by Administration Route (US$ Million), 2021–2032
Figure 13. Global Age Related Macular Degeneration Drug Market Share by Administration Route: 2025 vs 2032
Figure 14. Intravitreal injection Product Picture
Figure 15. Oral Administration Product Picture
Figure 16. Topical Eye Drops Product Picture
Figure 17. Other Product Picture
Figure 18. Global Age Related Macular Degeneration Drug Market Value by Application (US$ Million), 2021–2032
Figure 19. Global Age Related Macular Degeneration Drug Market Share by Application: 2025 & 2032
Figure 20. Hospitals
Figure 21. Clinics
Figure 22. Others
Figure 23. Global Age Related Macular Degeneration Drug Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 24. Global Age Related Macular Degeneration Drug Market Size (US$ Million), 2021–2032
Figure 25. Global Age Related Macular Degeneration Drug Sales (K Dose), 2021–2032
Figure 26. Global Age Related Macular Degeneration Drug Average Price (USD/Unit), 2021–2032
Figure 27. Age Related Macular Degeneration Drug Report Years Considered
Figure 28. Age Related Macular Degeneration Drug Sales Share by Manufacturers in 2025
Figure 29. Global Age Related Macular Degeneration Drug Revenue Share by Manufacturers in 2025
Figure 30. Top 5 and Top 10 Global Age Related Macular Degeneration Drug Players: Market Share by Revenue in Age Related Macular Degeneration Drug in 2025
Figure 31. Age Related Macular Degeneration Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 32. Global Age Related Macular Degeneration Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 33. North America Age Related Macular Degeneration Drug Sales Market Share by Country (2021–2032)
Figure 34. North America Age Related Macular Degeneration Drug Revenue Market Share by Country (2021–2032)
Figure 35. U.S. Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Canada Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Europe Age Related Macular Degeneration Drug Sales Market Share by Country (2021–2032)
Figure 38. Europe Age Related Macular Degeneration Drug Revenue Market Share by Country (2021–2032)
Figure 39. Germany Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. France Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. U.K. Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Italy Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Russia Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Asia Pacific Age Related Macular Degeneration Drug Sales Market Share by Region (2021–2032)
Figure 45. Asia Pacific Age Related Macular Degeneration Drug Revenue Market Share by Region (2021–2032)
Figure 46. China Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Japan Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. South Korea Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. India Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Australia Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Taiwan Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Indonesia Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Thailand Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Malaysia Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Philippines Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Latin America Age Related Macular Degeneration Drug Sales Market Share by Country (2021–2032)
Figure 57. Latin America Age Related Macular Degeneration Drug Revenue Market Share by Country (2021–2032)
Figure 58. Mexico Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 59. Brazil Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 60. Argentina Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 61. Middle East and Africa Age Related Macular Degeneration Drug Sales Market Share by Country (2021–2032)
Figure 62. Middle East and Africa Age Related Macular Degeneration Drug Revenue Market Share by Country (2021–2032)
Figure 63. Turkey Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 64. Saudi Arabia Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 65. U.A.E Age Related Macular Degeneration Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 66. Global Sales Market Share of Age Related Macular Degeneration Drug by Type (2021–2032)
Figure 67. Global Revenue Market Share of Age Related Macular Degeneration Drug by Type (2021–2032)
Figure 68. Global Age Related Macular Degeneration Drug Price (USD/Unit) by Type (2021–2032)
Figure 69. Global Sales Market Share of Age Related Macular Degeneration Drug by Application (2021–2032)
Figure 70. Global Revenue Market Share of Age Related Macular Degeneration Drug by Application (2021–2032)
Figure 71. Global Age Related Macular Degeneration Drug Price (USD/Unit) by Application (2021–2032)
Figure 72. Age Related Macular Degeneration Drug Value Chain
Figure 73. Channels of Distribution (Direct Vs Distribution)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed